Farncombe Family Institute of Digestive Health Research, McMaster University, Hamilton, Ontario, Canada.
Am J Gastroenterol. 2010 May;105(5):1062-70. doi: 10.1038/ajg.2009.657. Epub 2009 Nov 24.
Esophageal dilation often leads to long-lasting relief of dysphagia in eosinophilic esophagitis (EoE). The aim of this study was to define the effectiveness, safety, and patient acceptance of esophageal dilation in EoE. In addition, we examined the influence of dilation on the underlying esophageal inflammation.
Two databases including 681 EoE patients were reviewed. Cohort 1 consisted of patients treated with dilation alone, whereas cohort 2 included patients treated with a combination of dilation and antieosinophilic medication. Patients from cohort 1 underwent a prospective histological reexamination and an evaluation using a questionnaire.
In total, 207 EoE patients were treated with esophageal dilation, 63 in cohort 1 and 144 in cohort 2. Dilation led to a significant increase in esophageal diameter and to an improvement in dysphagia in both the cohorts (P<0.001). After dilation, dysphagia recurred after 23+/-22 months in cohort 1 and 20+/-14 months in cohort 2. No esophageal perforation or major bleeding occurred. Among the patients surveyed, 74% reported retrosternal pain after dilation; however, all were agreeable to repeated dilation if required. Eosinophil peak infiltration, eosinophil load, and EoE-associated histological signs were not significantly affected by esophageal dilation.
Esophageal dilation is highly effective in providing long-lasting symptom relief and can be performed safely with a high degree of patient acceptance. However, dilation is associated with postprocedural pain in most patients and does not influence the underlying inflammatory process. Symptom improvement despite persistence of inflammation suggests that tissue remodeling contributes substantially to symptom generation in EoE.
食管扩张术常可使嗜酸性粒细胞性食管炎(EoE)患者的吞咽困难长期缓解。本研究旨在确定食管扩张术在 EoE 中的有效性、安全性和患者接受程度。此外,我们还研究了扩张术对潜在食管炎症的影响。
我们对包含 681 例 EoE 患者的两个数据库进行了回顾。队列 1 包括仅接受扩张术治疗的患者,而队列 2 包括接受扩张术联合抗嗜酸性粒细胞药物治疗的患者。队列 1 中的患者接受了前瞻性组织学复查和问卷调查。
共有 207 例 EoE 患者接受了食管扩张术治疗,其中 63 例在队列 1 中,144 例在队列 2 中。两组患者的食管直径均显著增加,吞咽困难均明显改善(均 P<0.001)。扩张后,队列 1 中有 23±22 个月出现吞咽困难复发,队列 2 中有 20±14 个月出现吞咽困难复发。两组均未发生食管穿孔或大出血。在接受调查的患者中,74%的患者报告扩张后胸骨后疼痛;但所有患者均表示如有需要,可接受再次扩张。扩张术并未显著影响嗜酸性粒细胞峰浸润、嗜酸性粒细胞负荷和与 EoE 相关的组织学征象。
食管扩张术可有效提供长期症状缓解,安全性高,患者接受程度高。然而,扩张术与大多数患者术后疼痛相关,且不影响潜在的炎症过程。尽管炎症持续存在,但症状仍得到改善,提示组织重塑在 EoE 中对症状产生有重要贡献。